Racial and ethnic inclusiveness in clinical trials

Ethics and the Pharmaceutical Industry

Volumn , Issue , 2005, Pages 80-96

  Burroughs, Valentine J ^a  

^a NORTH GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84917115713     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511610769.010     Document Type: Chapter

References (58)

1. A report of the Institute of Medicine found that these disparities exist even after adjustment for differences in socioeconomic status, insurance coverage, income, age, comorbid conditions, expression of symptoms, and healthcare access-related factors. IOM Report, Unequal Treatment: Confronting Racial and Ethnic Disparities in Healthcare (Washington, DC: National Academy Press, 2002).
2. Bach PB, Cramer LD, Warren JL, and Begg CB, “Racial Differences in the Treatment of Early Stage Lung Cancer,” New England Journal of Medicine, 1999, 341: 1198-1205.
3. Bernabei R, Gambassi G, Lapane K, et al., “Management of Pain in Elderly Patients with Cancer,” JAMA, 1998, 279: 1877-82.
4. Schneidger EC, Leape LL, Weissman JS, et al., “Racial Differences in Cardiac Revascularization Rate: Does ‘Overuse’ Explain Higher Rates amongWhite Patients?” Annals of Internal Medicine, 2001, 135: 328-37.
5. Freeman HP, and Payne R, “Racial Injustice in Healthcare,” New England Journal of Medicine, 2000, 342: 1045-7.
6. Morrison RS, Wallenstein S, Natale DK, et al., “‘We Don’t Carry That’-Failure of Pharmacies in Predominately Nonwhite Neighborhoods to Stock Opioid Analgesics,” New England Journal of Medicine, 2000, 342: 1023-6.
7. Lee S, Mountain J, and Koenig BA, “The Meanings of ‘Race’ in the New Genomics; Implications for Health Disparities Research,” Yale Journal of Health Policy, Law, and Ethics, 2001, 1: 33-75.
8. Veterans Administration Cooperative Study Group on Antihypertensive Agents, “Comparison of Propranolol and Hydrochlorothiazide for the Initial Treatment of Hypertension I: Results of Short-Term Titration with Emphasis on Racial Differences in Response,” JAMA, 1982, 248: 1996-2003
9. Ahluwalia JS, and McNagny SE, “Smoking Prevalence and Desire to Quit in Inner City African American Walk-In Clinic Patients,” Clinical Research, 1993, 41: 752A.
10. Schwartz RS, “Racial Profiling in Medical Research,” New England Journal of Medicine, 2001, 344(18): 1392-3
11. Flack JM, Mensah GA, and Ferrario CM, “Using Angiotensin Converting Enzyme Inhibitors in African-American Hypertensives: A New Approach to Treating Hypertension and Preventing Target-Organ Damage,” Current Medical Research and Opinion, 2000, 16: 66-79.
12. Lin KM, and Poland RE, “Ethnicity, Culture, and Psychopharmacology,” in Bloom FF and Kupfer DJ, Eds., Psychopharmacology, The Fourth Generation of Progress (Nashville, TN: American College of Neuropsychopharmacology, 2000).
13. Strickland TL, Ranganath V, Lin KM, Poland RE, Mendoza R, and Smith MW, “Psychopharmacological Considerations in the Treatment of Black American Populations,” Psychopharmacology Bulletin, 1991, 27(4): 441-8.
14. Meyer UA and Zanger UM, “Molecular Mechanisms of Genetic Polymorphisms of Drug Metabolism,” Annual Review of Pharmacology and Toxicology, 1997, 37: 269-96.
15. Xie HG, Kim RB, Wood AJ, and Stein CM, “Molecular Basis of Ethnic Differences in Drug Disposition and Response,” Annual Review of Pharmacology and Toxicology, 2001, 41: 815-50.
16. Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, and Yunis EJ, “HLA-B38, DR4, Dqw3 and Clozapine-Induced Agranulocytosis in Jewish Patients with Schizophrenia,” Archives of General Psychiatry 1990, 47(10): 945-8.
17. Schwartz RS, “Racial Profiling in Medical Research,” New England Journal of Medicine, 2001, 344(18): 1392-3
18. Wood AJ, “Racial Differences in the Response to Drugs-Pointers to Genetic Differences,” NewEngland Journal of Medicine, May 3, 2001, 344(18): 1394-6.
19. Poolsup N, Li Wan Po A, Knight TL, “Pharmacogenetics and Psychopharmacotherapy,” Journal of Clinical Pharmacology and Therapeutics, 2000, 25(3): 197-220.
20. Vesell ES, “The Influence of Host Factors On Drug Response, I: Ethnic Background,” Rational Drug Therapy, 1979, 13(8): 1-7.
21. Lin KM, and Poland RE, “Ethnicity, Culture, and Psychopharmacology.”
22. Benowitz NL, “Substance Abuse: Dependence and Treatment,” in Melmon KL, Morelli HF, Hoffman BB, and Nierenberg DW, Eds., Clinical Pharmacology, Basic Principles in Therapeutics (NewYork: McGraw Hill, 1992).
23. Resnicow K, Futterman R, Weston RE, Royce J, Parms C, Freeman HP, and Orlandi MA, “Smoking Prevalence in Harlem, NewYork,” American Journal of Health Promotion, 1996, 10: 343-46.
24. Caraballo RS, Giovino GA, Pechacek TF, et al., “Racial and Ethnic Differences in Serum Nicotine Levels of Adult Cigarette Smokers,” Third National Health and Nutrition Examination Survey, 1988-91, JAMA, 1998, 280: 135-9
25. Perez-Stable EJ, Herrera B, Jacob P, and Benowitz NL, “Nicotine Metabolism and Intake in Black and White Smokers,” JAMA, 1998, 280: 152-6.
26. Royce JM, Hymowitz N, Corbett K, Hartwell TD, and Orlandi MA, for the COMMIT Research Group, “Smoking Cessation Factors among African Americans and Whites,” American Journal of Public Health, 1993, 83: 220-6
27. Giovino GA, Scholey MW, Zhu BP, et al., “Surveillance for Selected Tobacco-Use Behaviors-United States, 1900-1994,” in Centers for Disease Control Surveillance Summaries, November 18, 1994, Morbidity and MortalityWeekly Report, 1994, 43: 1-43
28. Fiore MC, Novotny TE, Pierce JP, Hatziandreu EJ, Patel KM, and Davis RM, “Trends in Cigarette Smoking in the U.S., the Changing Influence of Gender and Race,” JAMA, 1989, 261: 49-55.
29. Royce JM, Hymowitz N, Corbett K, Hartwell TD, Orlandi MA, for the COMMIT Research Group, “Smoking Cessation Factors among African Americans andWhites.”
30. Ahluwalia JS, Harris KJ, Catley D, Okuyemi KS, and Mayo MS, “Sustained-Release Bupropion for Smoking Cessation in African Americans. A Randomized Controlled Trial,” JAMA, 2002, 288: 468-74.
31. Noah B, “The Participation of Underrepresented Minorities in Clinical Research,” American Journal of Law and Medicine, 2003, Summer-Fall. Available at www.findarticles.com/cf dls/m6029/2-3 29/105518895?print.jhtml Accessed October 4, 2004.
32. Institute of Medicine Report, Unequal Treatment: Confronting Racial and Ethnic Disparities in Healthcare.
33. Kirsch IS, Jungebut A, Jenkins L, and Kolstad A, “Adult Literacy in America: A First Look at the Results of the National Adult Literacy Survey” (Washington, D.C.: Department of Education, 1993).
34. Finkelstein JA, Brown RW, Schneider LC, et al., “Quality of Care for Preschool Children with Asthma: The Role of Social Factors and Practice Setting,” Pediatrics, 1995, 95: 389-94.
35. Williams MV, Parker RM, Baker DW, Parikh K, Coates WC, and Nurss JR, “Inadequate Functional Health LiteracyamongPatients atTwoPublic Hospitals,” JAMA, 1995, 2714(21): 1677-82.
36. Nurss JR, el-Kebbi IM, Galliana DL, Zeimer DC, Musey VC, Lewis S, Liao Q, and Philips LS, “Diabetes in Urban African Americans: Functional Health Literacy of Municipal Hospital Outpatients with Diabetes,” Diabetes Education, 1995, 23(5): 563-8.
37. Schillinger D, Grumbach K, Piette J, et al., “Association of Health Literacy with Diabetes Outcomes,” JAMA, 2002, 288: 475-82.
38. Williams MV, Baker DW, Parker RM, and Nurss JR, “Relationship of Functional Health Literacy to Patients’ Knowledge of Their Chronic Disease:AStudy of Patients with Hypertension And Diabetes,” Archives of Internal Medicine, 1998, 158(2): 166-72.
39. Payer L, Medicine and Culture: Varieties of Treatment in the United States (New York: Penguin, 1988).
40. Kroll J, Linde P, Habenicht M, et al., “Medication Compliance, Antidepressant Blood Levels, and Side Effects in Southeast Asian Patients,” Journal of Clinical Psychopharmacology, 1990, 10: 279-83.
41. Mull JD, “Cross-Cultural Communication in the Physician’s Office,” Western Journal of Medicine, 1993, 159: 609-13.
42. Landy D, Ed., Culture, Disease, and Healing: Studies in Medical Anthropology (New York: MacMillan, 1977).
43. Lin KM, and Shen WW, “Pharmacotherapy for Southeast Asian Psychiatric Patients,” Journal of Nervous and Mental Diseases, 1991, 179: 346-50
44. Westermeyer J, Psychiatric Care of Migrants: A Clinical Guide (Washington, DC: American Psychiatric Press, 1989).
45. Purnell LD, and Paulanka BJ, Eds., Transcultural Health Care. A Culturally Competent Approach (Philadelphia: F. A. Davis, 1998).
46. Cappuccio FP, Duneclift SM, Atkinson RW, and Cook DG, “Use of Alternative Medicines in a Multi-ethnic Population,” Ethnic Diseases, 2001, 11(1): 11-18.
47. Bonkowsky JL, Frazer JK, Buchi KF, and Byington CL, “Metamizole Use by Latino Immigrants: A Common and Potentially Harmful Home Remedy,” Pediatrics, 2002, 109(6): e98.
48. Mishra R, “Some Chinese Herb Remedies Called Toxic.” Available at www.mdadvice.com/news/2001/02/01/medic/2531-0231-patny-times.htmlAccessed July 30, 2002.
49. Noah B, “The Participation of Underrepresented Minorities in Clinical Research,” American Journal of Law and Medicine, 2003, Summer-Fall.
50. Shavers VL, et al., “Factors That Influence African-Americans’ Willingness to Participate in Medical Research Studies,” Cancer 2001, 91: 233; and “Vital African American Recruitment Low in Prostate and Breast Cancer Drug Clinical Trials,” NBC Nightly News, September 15, 2002. Available at 2002 WL 3339803. Both cited in Noah, “The Participation of Underrepresented Minorities in Clinical Research” (note 25).
51. Heiat A, Gross CP, Krumholtz HM, et al., “Representation of the Elderly, Women, and Minorities in Heart Failure Clinical Trials,” Archives of Internal Medicine, 2002, 162: 1682, 1684, cited in Noah, “The Participation of Underrepresented Minorities in Clinical Research.” Noah points to the finding in this study that “only 15 percent of patients enrolled in these studies were racial or ethnic minorities.”
52. Svensson CK, “Representation of American Blacks in Clinical Trials of New Drugs,” JAMA, 1989, 261: 263-4, Table 1, cited in Noah, “The Participation of Underrepresented Minorities in Clinical Research.” Noah points out that “The study did not suggest that African-Americans had a lower incidence of the diseases in question than other population groups overrepresented in the clinical trials.”
53. Ahluwalia JS, and McNagny SE, “Smoking Prevalence and Desire to Quit in Inner City African American Walk-In Clinic Patients,” Clinical Research, 1993, 41: 752A.
54. King TE, “Racial Disparities in Clinical Trials,” New England Journal of Medicine, 2002, 346: 1400, 1402
55. Stone VE, “Race, Gender, Drug Use, and Participation in AIDS Clinical Trials,” Journal of General Internal Medicine, 1997, 12: 150. Both cited in Noah, “The Participation of Underrepresented Minorities in Clinical Research.”
56. Noah B, “The Participation of Underrepresented Minorities in Clinical Research.”
57. Taylor AL, Ziesche S, and Yancy C, “Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure,” New England Journal of Medicine, 2004; 351: 2049-57.
58. Kahn J, “How a Drug Becomes ‘Ethnic’: Law, Commerce and the Production of Racial Categories in Medicine,” Yale Journal of Health Policy, Law, and Ethics 2004; 4: 1-46.